JP2006519846A - 複素環式キナーゼインヒビター：使用および合成の方法 - Google Patents

複素環式キナーゼインヒビター：使用および合成の方法 Download PDF

Info

Publication number
JP2006519846A
JP2006519846A JP2006507031A JP2006507031A JP2006519846A JP 2006519846 A JP2006519846 A JP 2006519846A JP 2006507031 A JP2006507031 A JP 2006507031A JP 2006507031 A JP2006507031 A JP 2006507031A JP 2006519846 A JP2006519846 A JP 2006519846A
Authority
JP
Japan
Prior art keywords
alkyl
independently
heterocyclyl
heteroaryl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519846A5 (cg-RX-API-DMAC7.html
Inventor
エム． アーシャド スィッディクイ，
デービッド ベランガー，
チャオヤン ダイ，
リャンユン チャオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006519846A publication Critical patent/JP2006519846A/ja
Publication of JP2006519846A5 publication Critical patent/JP2006519846A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006507031A 2003-03-10 2004-03-10 複素環式キナーゼインヒビター：使用および合成の方法 Pending JP2006519846A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US46091003P 2003-04-07 2003-04-07
US46302503P 2003-04-15 2003-04-15
US50271003P 2003-09-12 2003-09-12
PCT/US2004/007286 WO2004080463A1 (en) 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis

Publications (2)

Publication Number Publication Date
JP2006519846A true JP2006519846A (ja) 2006-08-31
JP2006519846A5 JP2006519846A5 (cg-RX-API-DMAC7.html) 2008-02-21

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507031A Pending JP2006519846A (ja) 2003-03-10 2004-03-10 複素環式キナーゼインヒビター：使用および合成の方法

Country Status (5)

Country Link
EP (1) EP1601357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006519846A (cg-RX-API-DMAC7.html)
CA (1) CA2518398A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05009722A (cg-RX-API-DMAC7.html)
WO (1) WO2004080463A1 (cg-RX-API-DMAC7.html)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528027A (ja) * 2007-05-18 2010-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノリン誘導体
JP2010536872A (ja) * 2007-08-22 2010-12-02 アラーガン、インコーポレイテッド 治療用キノリンおよびナフタレン誘導体
JP2010540483A (ja) * 2007-09-27 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしてのキノリン誘導体
JP2011513350A (ja) * 2008-03-05 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ２−アミノキノリン類
JP2013514358A (ja) * 2009-12-17 2013-04-25 メルク・シャープ・エンド・ドーム・コーポレイション キノリンアミド化合物ｍ１受容体陽性アロステリックモデュレータ
JP2013536211A (ja) * 2010-08-27 2013-09-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換２−アミノ−キノリン−３−カルボキサミド
JP2017538673A (ja) * 2014-10-31 2017-12-28 ジェノシアンス ファルマ 新規抗癌剤としての置換２，４ジアミノキノリン
JP2019514951A (ja) * 2016-05-04 2019-06-06 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
JP2020045342A (ja) * 2009-06-12 2020-03-26 アビバックス Ａｉｄｓを治療する為に有用な化合物
JP2020523328A (ja) * 2017-06-14 2020-08-06 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｓｙｋ阻害薬及びその使用方法
US10975063B2 (en) 2009-06-12 2021-04-13 Abivax Compound, and production method thereof, and methods of treatment using the compound
JP2021535179A (ja) * 2018-09-05 2021-12-16 ジェノシアンス ファルマ 線維症、オートファジー、並びにカテプシンｂ（ｃｔｓｂ）、ｌ（ｃｔｓｌ）及びｄ（ｃｔｓｄ）関連疾患のための新しい薬剤としての置換２，４ジアミノキノリン
JP2022513844A (ja) * 2018-12-14 2022-02-09 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｓｙｋ阻害剤の塩及びその結晶形
US11441181B2 (en) 2013-01-17 2022-09-13 Abivax miRNA-124 as a biomarker
US11649211B2 (en) 2014-07-17 2023-05-16 Abivax Use of quinoline derivatives for the treatment of inflammatory diseases
US11992499B2 (en) 2018-12-20 2024-05-28 Abivax Quinoline derivatives for use in the treatment of inflammation diseases

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
WO2008059370A2 (en) 2006-11-17 2008-05-22 Pfizer Japan Inc. Substituted bicyclocarboxyamide compounds
CN101541753B (zh) 2006-12-07 2012-06-13 弗·哈夫曼-拉罗切有限公司 作为5-ht(5a)受体拮抗剂的2-氨基喹啉类化合物
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
AU2008260647A1 (en) * 2007-05-23 2008-12-11 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
BRPI0910253A2 (pt) 2008-03-07 2015-09-29 Hoffmann La Roche derivados de 2-aminoquinolina
AU2009221294A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinolines
MX2010009820A (es) 2008-03-12 2010-10-15 Hoffmann La Roche 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a.
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
MY159327A (en) 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
AU2010221417A1 (en) * 2009-03-02 2011-09-22 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
PH12012501535A1 (en) 2010-01-29 2012-10-22 Boehringer Ingelheim Int Substituted naphthyridines and their use as syk kinase inhibitors
EP2582676B1 (en) * 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2684167B1 (en) * 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
EA027506B1 (ru) 2011-04-01 2017-08-31 Астразенека Аб Способ лечения рака молочной железы
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
CA2834062A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
KR101986484B1 (ko) 2011-07-26 2019-06-10 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴놀린 및 이의 약제로서의 용도
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP3658560A4 (en) * 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2023099589A1 (en) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
US3479360A (en) * 1967-02-22 1969-11-18 Roussel Uclaf 2-methyl or phenyl-7- or 8-chloroquinolines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
JPS59219260A (ja) * 1982-12-24 1984-12-10 ロ−ン−プ−ラン・サント 新規なナフタレン−およびアザナフタレン−カルボキサミド誘導体、それを含有する製薬学的組成物、並びにそれらの製造法
JPH05310702A (ja) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd 抗炎症剤、免疫調整剤およびキノリン−２，４−ジカルボン酸ジアミド誘導体
WO2000051608A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US20010046991A1 (en) * 2000-03-01 2001-11-29 Siegfried Wurster Derivatives of quinoline as alpha-2 antagonists
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2002020488A2 (en) * 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002094789A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
WO2003011868A1 (en) * 2001-07-28 2003-02-13 Astrazeneca Ab Thienopyrimidinediones and their use in the modulation of autoimmune disease
WO2003018561A1 (en) * 2001-08-27 2003-03-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
BR0312204A (pt) * 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
MXPA05009723A (es) * 2003-03-10 2006-02-17 Schering Corp Analisis de ligando.

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
US3479360A (en) * 1967-02-22 1969-11-18 Roussel Uclaf 2-methyl or phenyl-7- or 8-chloroquinolines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
JPS59219260A (ja) * 1982-12-24 1984-12-10 ロ−ン−プ−ラン・サント 新規なナフタレン−およびアザナフタレン−カルボキサミド誘導体、それを含有する製薬学的組成物、並びにそれらの製造法
JPH05310702A (ja) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd 抗炎症剤、免疫調整剤およびキノリン−２，４−ジカルボン酸ジアミド誘導体
WO2000051608A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US20010046991A1 (en) * 2000-03-01 2001-11-29 Siegfried Wurster Derivatives of quinoline as alpha-2 antagonists
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2002020488A2 (en) * 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002094789A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
WO2003011868A1 (en) * 2001-07-28 2003-02-13 Astrazeneca Ab Thienopyrimidinediones and their use in the modulation of autoimmune disease
WO2003018561A1 (en) * 2001-08-27 2003-03-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528027A (ja) * 2007-05-18 2010-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノリン誘導体
JP2010536872A (ja) * 2007-08-22 2010-12-02 アラーガン、インコーポレイテッド 治療用キノリンおよびナフタレン誘導体
JP2014062103A (ja) * 2007-08-22 2014-04-10 Allergan Inc 治療用キノリンおよびナフタレン誘導体
JP2010540483A (ja) * 2007-09-27 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしてのキノリン誘導体
JP2011513350A (ja) * 2008-03-05 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ２−アミノキノリン類
US10975063B2 (en) 2009-06-12 2021-04-13 Abivax Compound, and production method thereof, and methods of treatment using the compound
JP7042245B2 (ja) 2009-06-12 2022-03-25 アビバックス Ａｉｄｓを治療する為に有用な化合物
US11014918B2 (en) 2009-06-12 2021-05-25 Abivax Compounds and pharmaceutical compositions containing at least one of the compounds
JP2020045342A (ja) * 2009-06-12 2020-03-26 アビバックス Ａｉｄｓを治療する為に有用な化合物
JP2013514358A (ja) * 2009-12-17 2013-04-25 メルク・シャープ・エンド・ドーム・コーポレイション キノリンアミド化合物ｍ１受容体陽性アロステリックモデュレータ
JP2013536211A (ja) * 2010-08-27 2013-09-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換２−アミノ−キノリン−３−カルボキサミド
US11441181B2 (en) 2013-01-17 2022-09-13 Abivax miRNA-124 as a biomarker
US11649211B2 (en) 2014-07-17 2023-05-16 Abivax Use of quinoline derivatives for the treatment of inflammatory diseases
US11649210B2 (en) 2014-07-17 2023-05-16 Abivax Use of quinoline derivatives for the treatment of inflammatory diseases
US12202804B2 (en) 2014-07-17 2025-01-21 Abivax In vitro or ex vivo methods for screening a quinoline derivative
JP2017538673A (ja) * 2014-10-31 2017-12-28 ジェノシアンス ファルマ 新規抗癌剤としての置換２，４ジアミノキノリン
JP2019514951A (ja) * 2016-05-04 2019-06-06 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
JP2020523328A (ja) * 2017-06-14 2020-08-06 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｓｙｋ阻害薬及びその使用方法
JP7299167B2 (ja) 2017-06-14 2023-06-27 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｓｙｋ阻害薬及びその使用方法
JP2021535179A (ja) * 2018-09-05 2021-12-16 ジェノシアンス ファルマ 線維症、オートファジー、並びにカテプシンｂ（ｃｔｓｂ）、ｌ（ｃｔｓｌ）及びｄ（ｃｔｓｄ）関連疾患のための新しい薬剤としての置換２，４ジアミノキノリン
JP2022513844A (ja) * 2018-12-14 2022-02-09 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｓｙｋ阻害剤の塩及びその結晶形
JP7472138B2 (ja) 2018-12-14 2024-04-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｓｙｋ阻害剤の塩及びその結晶形
US11992499B2 (en) 2018-12-20 2024-05-28 Abivax Quinoline derivatives for use in the treatment of inflammation diseases

Also Published As

Publication number Publication date
MXPA05009722A (es) 2006-03-09
WO2004080463A1 (en) 2004-09-23
CA2518398A1 (en) 2004-09-23
EP1601357A4 (en) 2007-10-03
EP1601357A1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
JP2006519846A (ja) 複素環式キナーゼインヒビター：使用および合成の方法
JP2006519846A5 (cg-RX-API-DMAC7.html)
US8242271B2 (en) Heterocyclic compounds and uses thereof
KR102083693B1 (ko) Ccr9 길항제로써 피라졸-1-일 벤젠 술폰아미드
JP2012525390A (ja) 置換イミダゾ［１，２−ａ］ピリジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法
KR19990022574A (ko) 이미다졸 화합물
MXPA03002294A (es) Compuestos de pirazol utiles como inhibidores de proteina cinasa.
WO2012008564A1 (ja) 含窒素芳香族複素環誘導体
EP1543003B1 (en) Imidazo¬1,2-a|pyridines
BG99879A (bg) Инхибитори на нiv реверсивна транскриптаза
US20080004325A1 (en) PTP1B inhibitors
AU2008345696A1 (en) Benzimidazole compounds
JP2013522364A (ja) 置換イミダゾ［１，２−ｂ］ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法
JP2018507255A (ja) 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体
CA2548009A1 (en) Naphthyridine derivatives and their use as modulators of muscarinic receptors
JP2022549601A (ja) ヘテロアリール血漿カリクレインインヒビター
JP2022545007A (ja) インターフェロン遺伝子の刺激因子ｓｔｉｎｇの単環式アゴニスト
US20080119515A1 (en) Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
JPWO1998042680A1 (ja) 新規なアニリド化合物及びこれを含有する医薬
HK1165415A (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070302

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101026